Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year — ERASURE

Moderate to Severe Plaque-type Psoriasis Clinical Trial

Official title:
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Status Completed

Clinical Trial Summary

This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Moderate to Severe Plaque-type Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT01365455
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	June 2011
Completion date	April 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01555125` - First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks	Phase 3
Completed	`NCT01544595` - Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab	Phase 3
Completed	`NCT02474069` - Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis	Phase 3
Completed	`NCT01406938` - Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens	Phase 3